Why is "Carbapenem" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-30 15:09:57
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Carbapenem entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-30 and was most recently seen on 2026-06-30.
Wikipedia Overview
Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs - AJMC
-
The shift from “MIC-Only” back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance - ASM Journals
-
Carbapenem-resistance oprD mutations reshape Pseudomonas aeruginosa host-pathogen interactions during infection - Nature
-
Transcriptomic investigations of polymyxins and colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii - Science Partner Journals
-
Carbapenem‐Resistant Gram‐Negative Bacilli in Mauritania: A Major Public Health Threat - Wiley Online Library
-
FDA Approves Utebzi, First Oral Carbapenem for Complicated UTIs - The Clinical Trial Vanguard
-
Current progress in antibacterial agents for carbapenem-resistant enterobacterales - Frontiers
-
Utebzi Approved as First Oral Carbapenem Antibiotic for cUTIs - Infectious Disease Advisor
-
FDA Approves Tebipenem Pivoxil as First Oral Carbapenem for Complicated Urinary Tract Infections - Contagion Live
-
Utebzi: First oral carbapenem for complicated urinary tract infections in adults - WebMD
-
FDA Approves Utebzi, First Oral Carbapenem for cUTI - Infectious Disease Special Edition
-
Oral Carbapenem Wins FDA Approval for cUTIs - Conexiant
-
First Oral Carbapenem Approved for Complicated UTIs - MedPage Today
-
FDA approves new oral antibiotic for complicated urinary tract infections - CIDRAP
-
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico - Nature
-
A No-Carb Diet: An Overview of Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacterales - Contagion Live
-
) genes among carbapenem-resistant Enterobacteriaceae (CRE) in Jazan Region, Saudi Arabia - Nature
-
Gene-specific reversal of carbapenem-resistant Pseudomonas aeruginosa via phage-delivered CRISPR-Cas13a | npj Antimicrobials and Resistance - Nature
-
Nationwide genomic surveillance of carbapenem- and colistin-resistant Klebsiella pneumoniae bloodstream isolates in Thailand (2020–2024) - Nature
-
Molecular epidemiology of OXA-1054, a novel carbapenem-hydrolysing Class D β-lactamase, in Enterobacteriaceae isolated from wastewaters - Nature
-
Risk factors and treatment advances for carbapenem-resistant Enterobacteriaceae infections in the urinary tract - Frontiers
-
in a highly drug-resistant Salmonella Stanley ST29 strain in China - ASM Journals
-
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Yahoo Finance
-
Integrated experimental and computational evaluation of Anagallis foemina derived terpenoids against carbapenem resistant Acinetobacter baumannii - Nature
-
Analysis plan for the survey of carbapenem-resistant Enterobacterales 2025 (CRE25 survey) - European Centre for Disease Prevention and Control (ECDC)
-
Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates | Scientific Reports - Nature
-
The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales - ASM Journals
-
In vitro activity of imipenem–relebactam against carbapenem-resistant Pseudomonas aeruginosa: correlation with carbapenem MICs and association with β-lactamase classes - Frontiers
-
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) - Yahoo Finance
-
Differences in β-lactamase activity and carbapenem resistance among the Bacillus cereus group - ASM Journals
-
FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs - Drug Topics
-
Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects - ASM Journals
-
Decoding Carbapenem Resistance: Detection of Carbapenemase Genes in Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii - Cureus
-
Clinical Impact of Biofilm-Producing Carbapenem-Resistant Acinetobacter baumannii: Diagnosis and Treatment Challenges - Cureus
-
An Oral Antibiotic Pill Proved Just as Effective as IV Treatment for Drug-Resistant UTIs - Medical Daily
-
Colistin Resistance in Klebsiella pneumoniae: Mechanisms, Detection, and Clinical Impact - Cureus
-
Environmental contamination of carbapenem-resistant gram-negative bacteria away from isolated patients in intensive care unit: a comprehensive surveillance study - Nature
-
CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria - Centers for Disease Control and Prevention | CDC (.gov)
-
Machine learning-based prediction of carbapenem-resistant Klebsiella pneumoniae infection risk and prognosis - Frontiers
-
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GSK
-
Emergence of carbapenem-resistant Phytobacter diazotrophicus in hospital effluent in Brazil - Frontiers
-
GSK claims FDA okay for first oral carbapenem antibiotic - pharmaphorum
-
Genomic evidence of convergence of multidrug resistance and enhanced virulence in carbapenem- and colistin-resistant Klebsiella pneumoniae from Turkey - ASM Journals
-
Environmental reservoirs account for high levels of carbapenem resistance genes in wastewater - ASM Journals
-
Emergence of a carbapenem-resistant atypical uropathogenic Escherichia coli clone as an increasing cause of urinary tract infection - Nature
-
Surge in NDM-Producing Carbapenem-Resistant Enterobacterales (NDM-CRE) Infections Raises Treatment and Infection Control Challenges in U.S. Healthcare Settings - Vera Health
-
Phenotypic characterisation and prevalence of carbapenem-resistant Enterobacterales in a tertiary care centre in Bihar India - Nature
-
Spread of ST11-O13/KL47 hypervirulent carbapenem-resistant Klebsiella pneumoniae isolates in China - Nature
-
What It Takes to Stop Carbapenem-Resistant Organisms: Lessons From the Front Lines in Ethiopia and India - Infection Control Today
-
Risk factors, prognostic impact, and antimicrobial susceptibility profiles of carbapenem-resistant Acinetobacter baumannii bloodstream infections: a retrospective cohort study - Nature
-
Clinico-Microbiological Profile of Carbapenem-Resistant Acinetobacter baumannii Isolates From Intensive Care Unit Patients and In Vitro Activity of Sulbactam-Durlobactam: A Cross-Sectional Study From Eastern India - Cureus
-
Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial - Contagion Live
-
Synergistic effects of colistin-based combinations against colistin and carbapenem-resistant Klebsiella pneumoniae isolated from nosocomial bloodstream infections - Nature
-
Emergence of Carbapenem-Resistant Salmonella Typhi Harboring blaNDM-5 in India: Genomic Evidence from a Multicenter Study - Frontiers
-
Methodological quality assessment tool for observational studies comparing treatment effectiveness in infectious diseases: a Delphi consensus and application to studies on bloodstream infections due to carbapenem-resistant Enterobacterales - The Lancet
-
Carbapenem-resistant Salmonella Derby harboring a plasmid carrying blaNDM-1 from a clinical case in China - Frontiers
-
Latin America and the Caribbean Carbapenem Susceptibility Test Strips - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
-
In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii - Nature
-
GSK wins FDA approval for first oral carbapenem antibiotic - Investing.com
-
IDSA Guideline Recommendations for Carbapenem-Resistant Acinetobacter Baumannii - Pharmacy Times – Pharmacy Practice News and Expert Insights
-
Complicated UTI: first oral carbapenem option gains FDA approval - Vera Health
-
FDA approves first oral carbapenem therapy for cUTIs - The Pharma Letter
-
Case Report: Psoas abscess caused by Carbapenem-Resistant Enterobacteriaceae in a CO poisoning patient - Frontiers
-
Antimicrobial Resistance Laboratory Network | ARLN - Centers for Disease Control and Prevention | CDC (.gov)
-
FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections - Pharmaceutical Executive
-
Metabolic reprogramming enhances the susceptibility of multidrug- and carbapenem-resistant bacteria to antibiotics - Nature
-
Optimism After Open-Label Study as Rising Carbapenem Resistance Shapes Future Treatment Guidance - Contagion Live
-
Distribution of ESBL-producing and carbapenem-resistant E. coli and Salmonella spp. in retail chicken meat and live bird market sewage in Bangladesh - PLOS
-
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs - Manufacturing Chemist
-
Two Virulent Bacteriophages Targeting Carbapenem-Resistant Raoultella planticola - Frontiers
-
Continuity of carbapenem resistance determinants in carioca river and Rodrigo de Freitas Lagoon, Rio de Janeiro, Brazil, after decade - Nature
-
The oral penems and carbapenems - ASM Journals
-
The Rising Menace: Carbapenem-Resistant Klebsiella pneumoniae in a Tertiary Care Center and Co-dominance of blaNDM, blaOXA-48 Along With the Emergence of blaVIM - Cureus
-
Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections - Nature
-
Investigating the prevalence of class 1, 2, and 3 integrons in carbapenem-resistant Acinetobacter baumannii isolated from burn wound infections - Nature
-
Comparison of appropriate antimicrobial monotherapy and combination therapy in patients with carbapenem-resistant gram-negative bacilli bloodstream infections: a multicenter retrospective cohort study - ASM Journals
-
Rapid screening for carbapenemase-producing carbapenem-resistant Enterobacterales : clinical implementation of an immunochromatographic test using broth-enriched rectal swabs - ASM Journals
-
Oral tebipenem HBr matches IV carbapenem in phase 3 cUTI trial - Contemporary OB/GYN
-
Personalised bactericidal combination regimens against carbapenem-resistant Pseudomonas aeruginosa - Nature
-
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Benzinga
-
Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistant Acinetobacter baumannii - ASM Journals
-
Study finds carbapenem-resistant bacteria in nearly 2% of gram-negative isolates from dogs, cats - CIDRAP
-
Phenotypic and genotypic investigation of carbapenemases in carbapenem-resistant Klebsiella pneumoniae isolates - Springer Nature Link
-
Complicated UTI: first oral carbapenem option gains FDA approval - Vera Health
-
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities - Nature
-
Complicated UTI: first oral carbapenem option now FDA approved - Vera Health
-
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line - Fierce Pharma
-
CAMEL Interim Data: Avycaz and Vabomere Show Similar Outcomes in KPC-CRE Infections - Infectious Disease Special Edition
-
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US - Quiver Quantitative
-
A conserved KL2-capsule-related phage-resistant mechanism in carbapenem-resistant Acinetobacter baumannii is surmountable by a rationally selected dual-phage cocktail - Frontiers
-
Correction: Carbapenem-resistant Klebsiella pneumoniae from clinical infections: a multifactorial analysis of resistance, virulence, and biofilm potential - Frontiers
-
BBB-Crossing Ionizable Upconversion Nanoparticles for Synergistic Therapy of Carbapenem-Resistant Central Nervous System Infection | Research - Science Partner Journals
-
FDA approves Utebzi, first oral carbapenem for certain UTIs - Investing.com
-
Fungating Breast Carcinoma Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection in a Patient With Severe Blood-Injection-Injury Phobia: A Case Report - Cureus
-
Isolation and genomic analysis of seven phages active against carbapenem-resistant Klebsiella pneumoniae - ASM Journals
-
Chemically tailored anionic antibiotic adjuvants targeting divalent cations to overcome carbapenem resistance in gram-negative bacteria - Science | AAAS
-
CRAB Infections Sulbactam-Durlobactam Xacduro - Infectious Disease Special Edition
-
False positive NDM and OXA-48 results of the lateral flow carbapenem-resistant K.N.I.V.O. Detection K-set in Stenotrophomonas maltophilia: Time for official performance evaluation of LFAs? - Elsevier
-
Case Report:Psoas Abscess Caused by Carbapenem-Resistant Enterobacteriaceae in a CO Poisoning Patient - Frontiers
-
GSK will file oral carbapenem for complicated UTIs this year - pharmaphorum
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.